Literature DB >> 28357564

The use of nonhuman primate models to understand processes in Parkinson's disease.

Javier Blesa1,2, Inés Trigo-Damas1,2, Natalia López-González Del Rey1,2, José A Obeso3,4.   

Abstract

Research with animal models has led to critical health advances that have saved or improved the lives of millions of human beings. Specifically, nonhuman primate's genetic and anatomo-physiological similarities to humans are especially important for understanding processes like Parkinson's disease, which only occur in humans. Unambiguously, the unique contribution made by nonhuman primate research to our understanding of Parkinson's disease is widely recognized. For example, monkeys with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) parkinsonisms are responsive to dopamine replacement therapies, mimicking what is seen in PD patients. Moreover, groundbreaking neuroanatomical and electrophysiological studies using this monkey model in the 1980s and 1990s enabled researchers to identify the neuronal circuits responsible for the cardinal motor features of PD. This led to the development of subthalamic surgical ablation and deep brain stimulation, the current therapeutic gold standard for neurosurgical treatment. More recently, the mechanisms of α-synuclein spreading testing the prion hypothesis for PD have yielded exciting results. In this review, we discuss and highlight how the findings from nonhuman primate research contribute to our understanding of idiopathic Parkinson's disease.

Entities:  

Keywords:  Animal models; DBS; MPTP; Nonhuman primates; Parkinson’s disease

Mesh:

Substances:

Year:  2017        PMID: 28357564     DOI: 10.1007/s00702-017-1715-x

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  178 in total

1.  Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial.

Authors:  William J Marks; Raymond T Bartus; Joao Siffert; Charles S Davis; Andres Lozano; Nicholas Boulis; Jerrold Vitek; Mark Stacy; Dennis Turner; Leonard Verhagen; Roy Bakay; Raymond Watts; Barton Guthrie; Joseph Jankovic; Richard Simpson; Michele Tagliati; Ron Alterman; Matthew Stern; Gordon Baltuch; Philip A Starr; Paul S Larson; Jill L Ostrem; John Nutt; Karl Kieburtz; Jeffrey H Kordower; C Warren Olanow
Journal:  Lancet Neurol       Date:  2010-10-20       Impact factor: 44.182

2.  Rhesus hyperkinesia by subthalamic lesion.

Authors:  J R WHITTIER
Journal:  Fed Proc       Date:  1948-03

Review 3.  α-Synuclein-Based Animal Models of Parkinson's Disease: Challenges and Opportunities in a New Era.

Authors:  Naomi P Visanji; Jonathan M Brotchie; Lorraine V Kalia; James B Koprich; Anurag Tandon; Joel C Watts; Anthony E Lang
Journal:  Trends Neurosci       Date:  2016-10-21       Impact factor: 13.837

4.  Convection-enhanced delivery of AAV vector in parkinsonian monkeys; in vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach.

Authors:  K S Bankiewicz; J L Eberling; M Kohutnicka; W Jagust; P Pivirotto; J Bringas; J Cunningham; T F Budinger; J Harvey-White
Journal:  Exp Neurol       Date:  2000-07       Impact factor: 5.330

5.  Neurochemical plasticity in the enteric nervous system of a primate animal model of experimental Parkinsonism.

Authors:  T Chaumette; T Lebouvier; P Aubert; B Lardeux; C Qin; Q Li; D Accary; E Bézard; S Bruley des Varannes; P Derkinderen; M Neunlist
Journal:  Neurogastroenterol Motil       Date:  2008-12-05       Impact factor: 3.598

Review 6.  Initial clinical manifestations of Parkinson's disease: features and pathophysiological mechanisms.

Authors:  Maria C Rodriguez-Oroz; Marjan Jahanshahi; Paul Krack; Irene Litvan; Raúl Macias; Erwan Bezard; José A Obeso
Journal:  Lancet Neurol       Date:  2009-12       Impact factor: 44.182

7.  The primate subthalamic nucleus. III. Changes in motor behavior and neuronal activity in the internal pallidum induced by subthalamic inactivation in the MPTP model of parkinsonism.

Authors:  T Wichmann; H Bergman; M R DeLong
Journal:  J Neurophysiol       Date:  1994-08       Impact factor: 2.714

Review 8.  The value of nonhuman primates in drug abuse research.

Authors:  Elise M Weerts; William E Fantegrossi; Amy K Goodwin
Journal:  Exp Clin Psychopharmacol       Date:  2007-08       Impact factor: 3.157

Review 9.  Levodopa therapy for Parkinson disease: A look backward and forward.

Authors:  Peter A LeWitt; Stanley Fahn
Journal:  Neurology       Date:  2016-04-04       Impact factor: 9.910

10.  Neuroimaging Analysis of the Dopamine Basis for Apathetic Behaviors in an MPTP-Lesioned Primate Model.

Authors:  LinLin Tian; Yuanxuan Xia; Hubert P Flores; Meghan C Campbell; Stephen M Moerlein; Joel S Perlmutter
Journal:  PLoS One       Date:  2015-07-02       Impact factor: 3.240

View more
  8 in total

Review 1.  Is Braak staging valid for all types of Parkinson's disease?

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2018-06-25       Impact factor: 3.575

2.  Early onset of sleep/wake disturbances in a progressive macaque model of Parkinson's disease.

Authors:  Aurélie Davin; Stéphan Chabardès; Hayat Belaid; Daniel Fagret; Loic Djaileb; Yves Dauvilliers; Olivier David; Napoléon Torres-Martinez; Brigitte Piallat
Journal:  Sci Rep       Date:  2022-10-19       Impact factor: 4.996

3.  Non-human primate research of basal ganglia and movement disorders: advances and challenges.

Authors:  Yoland Smith; Adriana Galvan
Journal:  J Neural Transm (Vienna)       Date:  2018-03       Impact factor: 3.575

Review 4.  New roles for dopamine in motor skill acquisition: lessons from primates, rodents, and songbirds.

Authors:  A N Wood
Journal:  J Neurophysiol       Date:  2021-05-12       Impact factor: 2.974

5.  Starting and stopping movement by the primate brain.

Authors:  Roger Lemon; Alexander Kraskov
Journal:  Brain Neurosci Adv       Date:  2019-03-15

Review 6.  The Challenge and Opportunity to Diagnose Parkinson's Disease in Midlife.

Authors:  Alexander Kilzheimer; Thomas Hentrich; Simone Burkhardt; Julia M Schulze-Hentrich
Journal:  Front Neurol       Date:  2019-12-17       Impact factor: 4.003

7.  Cardiac tyrosine hydroxylase activation and MB-COMT in dyskinetic monkeys.

Authors:  Lorena Cuenca-Bermejo; Pilar Almela; Pablo Gallo-Soljancic; José E Yuste; Vicente de Pablos; Víctor Bautista-Hernández; Emiliano Fernández-Villalba; María-Luisa Laorden; María-Trinidad Herrero
Journal:  Sci Rep       Date:  2021-10-06       Impact factor: 4.379

Review 8.  Nanotechnology-Based Drug Delivery Strategies to Repair the Mitochondrial Function in Neuroinflammatory and Neurodegenerative Diseases.

Authors:  Luis F González; Lorenzo E Bevilacqua; Rodrigo Naves
Journal:  Pharmaceutics       Date:  2021-12-01       Impact factor: 6.321

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.